Learn More
OBJECTIVE To evaluate the efficacy of a second year of pegaptanib sodium therapy in patients with neovascular age-related macular degeneration (AMD). DESIGN Two concurrent, multicenter, randomized, double-masked, sham-controlled studies (V.I.S.I.O.N. [Vascular Endothelial Growth Factor Inhibition Study in Ocular Neovascularization] trials). PARTICIPANTS(More)
OBJECTIVE To describe peripapillary detachment in pathologic myopia (PDPM), a newly recognized fundus lesion. DESIGN Retrospective medical record review. METHODS We evaluated a series of myopic eyes that had a yellow-orange elevation of the retina and retinal pigment epithelium at the inferior border of the myopic conus. RESULTS Twenty eyes of 15(More)
OBJECTIVE To study effects of intravitreal pegaptanib (Macugen) on retinal neovascularization. DESIGN Retrospective analysis of a randomized clinical trial. PARTICIPANTS, INTERVENTION, AND MAIN OUTCOME MEASURES: Individuals with retinal neovascularization identified from a multicenter, randomized, controlled trial evaluating pegaptanib for treatment of(More)
OBJECTIVE To determine the nature and frequency of polypoidal choroidal vasculopathy (PCV) in a series of patients suspected of having neovascularized age-related macular degeneration (AMD). METHODS A prospective analysis of 167 consecutive, newly diagnosed patients aged 55 years or older with presumed neovascularized AMD was performed. All patients were(More)
AIMS To evaluate the safety of up to 3 years of pegaptanib sodium therapy in the treatment of neovascular age-related macular degeneration (NV-AMD). METHODS Two concurrent, prospective, multicentre, double-masked studies randomised subjects with all angiographic lesion compositions of NV-AMD to receive intravitreous pegaptanib sodium (0.3, 1 and 3 mg) or(More)
OBJECTIVE To differentiate polypoidal choroidal vasculopathy (PCV) from central serous chorioretinopathy (CSC). DESIGN A retrospective, observational case series. PARTICIPANTS Thirteen patients originally diagnosed with CSC proved to have PCV after more extensive evaluation and follow-up. METHODS A clinical and angiographic review of patients with(More)
Using a sensitive radioimmunoassay to homologous mouse alpha-crystallin, it was established that autoantibodies are produced to this self constituent in mice after rupture of the lens capsule by needling. Antibody to lens crystallin was detected within 4 days of lens rupture and persisted for 24 days, suggesting that these mice are not tolerant to(More)
OBJECTIVE To evaluate the safety and efficacy of pegaptanib sodium injection (pegaptanib) in the treatment of diabetic macular edema (DME). DESIGN Randomized, double-masked, multicenter, dose-ranging, controlled trial. PARTICIPANTS Individuals with a best-corrected visual acuity (VA) between 20/50 and 20/320 in the study eye and DME involving the center(More)